Pharmacokinetic optimization of antiretroviral therapy in pregnancy

Clinical Pharmacokinetics

Volumn 51, Issue 10, 2012, Pages 639-659

  Buckoreelall, Kajal ^a   Cressey, Tim R ^b,c,d   King, Jennifer R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; CYTOCHROME P450 ISOENZYME; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; GLUCURONOSYLTRANSFERASE 1A1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZIDOVUDINE;

ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BIRTH DEFECT; BONE DISEASE; BREAST FEEDING; BREAST MILK; CD4 LYMPHOCYTE COUNT; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MILK LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; FATTY LIVER; FIRST TRIMESTER PREGNANCY; GLOMERULUS FILTRATION RATE; HALLUCINATION; HEART INFARCTION; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INFECTION RISK; INSOMNIA; KIDNEY BLOOD FLOW; KIDNEY DISEASE; LABOR; LACTIC ACIDOSIS; LIPODYSTROPHY; LIPOPHILICITY; LIVER METABOLISM; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MATERNAL BLOOD; MAXIMUM PLASMA CONCENTRATION; MENTAL CONCENTRATION; NAUSEA; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PERINATAL INFECTION; PHYSIOLOGICAL PROCESS; PLACENTAL TRANSFER; PLASMA PROTEIN BINDING; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RASH; RECOMMENDED DRUG DOSE; REVIEW; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL CORD BLOOD; URINARY EXCRETION; VERTICAL TRANSMISSION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PLACENTA; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84873466060     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0002-0     Document Type: Review

References (132)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-80.
2. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine: Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341(6):385-93.
3. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission: Women and Infants Transmission Study Group. N Engl J Med. 1999;341(6):394-402.
4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. September 14, 2011, p. 1-207. http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf. Accessed 7 May 2012.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011, p. 1-167. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 7 May 2012.
6. Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000;30(Suppl 2):S151-9.
7. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71-5.
8. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737-45.
9. Weinberg A, Forster-Harwood J, Davies J, et al. Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol. 2011;2011:867674.
10. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19(8):795-9.
11. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071-87.
12. Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol 2010; 37(4):907-27, xi.
13. Dawes M, Chowienczyk PJ. Drugs in pregnancy: pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):819-26.
14. Kashuba AD, Dyer JR, Kramer LM, et al. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43(8):1817-26.
15. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther. 1980;10(2):301-28.
16. Aweeka FT, Stek A, Best BM, et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010;11(4):232-8.
17. Kiser J, Mawhinney S, Kinzie K, et al. Total and unbound lopinavir/ritonavir pharmacokinetics in a concentration-guided study of HIV-infected women throughout pregnancy and post-partum [abstract no. 946]. In: Programs and abstracts of the 16th conference on retroviruses and opportunistic infections; 2009 Feb 8-11; Montreal, Canada. Alexandria: Foundation for Retrovirology and Human Health, 2010.
18. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011;2011:783528.
19. Yankowitz J, Neibyl J. Drug therapy in pregnancy. 3rd ed. Philadelphia: Lippincott William Wilkins; 2001.
20. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. 2010 version; p. 1-105. World Health Organization. http://www.who.int/hiv/pub/mtct/ antiretroviral2010/en/index.html. Accessed 7 May 2012.
21. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
22. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-32.
23. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121-2.
24. Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006;20(4):553-60.
25. Emtricitabine (Emtriva) [package insert]. Forest City: Gilead, Inc.; 2011.
26. Stek A, Best B, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012;13(4):226-35.
27. Davison JM. Kidney function in pregnant women. Am J Kidney Dis. 1987;9(4):248-52.
28. Lamivudine (Epivir) [package insert]. Forest City: Gilead, Inc.; 2011.
29. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178(5):1327-33.
30. Benaboud S, Treluyer JM, Urien S, et al. Pregnancy-related effects on Lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56(2):776-82.
31. Stavudine (Zerit) [package insert]. Princeton: Bristol-Myers Squibb; 2012.
32. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004;190(12):2167-74.
33. Tenofovir disoproxil fumurate (Viread) [package insert]. Forest City: Gilead, Inc.; 2012.
34. Foster C, Lyall H, Olmscheid B, et al. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med. 2009;10(7):397-406.
35. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011;55(12):5914-22.
36. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595-612.
37. Hirt D, Urien S, Ekouevi DK, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009;85(2):182-9.
38. Burchett S, Best B, Mirochnick M, et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum [abstract no. 738b]. In: Programs and abstracts of the 14th conference on retroviruses and opportunistic infections; 2007 Feb 25-28; Los Angeles, California. Alexandria: Foundation for Retrovirology and Human Health; 2007.
39. Benaboud S, Hirt D, Launay O, et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother. 2012;56(2):857-62.
40. Barbier O, Turgeon D, Girard C, et al. 3′-Azido-3′- deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos. 2000;28(5):497-502.
41. Singlas E, Pioger JC, Taburet AM, et al. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients. Eur J Clin Pharmacol. 1989;36(6):639-40.
42. Sperling RS, Roboz J, Dische R, et al. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol. 1992;9(4):247-9.
43. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991;163(2):226-32.
44. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287-300.
45. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29(10):865-74.
46. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16(2):299-300.
47. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162(3):355.
48. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59(3):245-52.
49. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391-400.
50. Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother. 2009;64(6):1265-73.
51. Nevirapine (Viramune) [package insert]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2011.
52. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates: Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178(2):368-74.
53. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13(4):479-86.
54. Eshleman SH, Church JD, Chen S, et al. Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42(4):518-21.
55. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14(11):F111-5.
56. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351(3):229-40.
57. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356(2):135-47.
58. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38(3):283-8.
59. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009;6(10):e1000172.
60. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis. 2012;54(2):285-93.
61. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9(4):214-20.
62. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr. 2010;55(3):345-50.
63. Etravirine (Intelence) [package insert]. Raritan: Tibotec, Inc.; 2011.
64. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS. 2009;23(3):434-5.
65. Izurieta P, Kakuda TN, Feys C, et al. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011;12(4):257-8.
66. Rilpivirine (Edurant) [package insert]. Raritan: Tibotec, Inc.; 2011.
67. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32(3):194-209.
68. Atazanavir (Reyataz) [package insert]. Princeton: Bristol Myers Squibb; 2012.
69. King JR, Wynn H, Brundage R, et al. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004;43(5):291-310.
70. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633-9.
71. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84(2):248-53.
72. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007;21(18):2409-15.
73. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med. 2011;12(9):570-9.
74. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412-9.
75. Mirochnick M, Stek A, Capparelli EV, et al. Pharmacokinetics of increased dose of atazanavir with and without tenofovir during pregnancy. In: Programs and abstracts of the 12th international workshop on clinical pharmacology of HIV therapy; 2011 Apr 13-15; Miami, FL. Utrecht: Virology Education B.V.; 2011.
76. Pacanowski J, Bollens D, Poirier JM, et al. Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS. 2009;23(14):1923-4.
77. Capparelli E. Pharmacokinetics of darunavir once or twice daily during and after pregnancy [abstract no. P-72]. In: Programs and abstracts of the 3rd international workshop on HIV pediatrics; 2011 Jul 15-16; Rome, Italy. Utrecht: Virology Education B.V.; 2011.
78. Capparelli E, Stek A, BM B, et al. Boosted fosamprenavir pharmacokinetics during pregnancy [abstract no. 908]. In: Programs and abstracts of the 17th conference on retroviruses and opportunistic infections; 2010 Feb 16-19; San Francisco, CA. Alexandria: Foundation for Retrovirology and Human Health; 2010.
79. Cespedes M, Ford S, Pakes G, et al. Pharmacokinetics, cord blood concentrations, and tolerability of boosted fosamprenavir (FPV) in pregnancy [abstract no. TUPE278]. In: 6th IAS conference on HIV pathogenesis, treatment and prevention; 2011 Jul 17-20; Rome.
80. Boyd MA, Srasuebkul P, Khongphattanayothin M, et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir Ther. 2006;11(2):223-32.
81. Cressey TR, Leenasirimakul P, Jourdain G, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother. 2005;55(6):1041-4.
82. Hayashi S, Beckerman K, Homma M, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000;14(8):1061-2.
83. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51(2):783-6.
84. Ghosn J, De Montgolfier I, Cornelie C, et al. Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy. Antimicrob Agents Chemother. 2008;52(4):1542-4.
85. Cressey TR, BM B, Achalapong J, et al. Effect of pregnancy on pharmacokinetics of indinavir boosted ritonavir. In: Programs and abstracts of the 13th international workshop on clinical pharmacology of HIV therapy; 2012 Apr 16-18; Barcelona, Spain. Utrecht: Virology Education B.V.; 2012.
86. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20(15):1931-9.
87. Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010;24(14):2193-200.
88. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS. 2007;21(8):1053-4.
89. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007; 21(5):643-5. Epub 2007/02/23.
90. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008;49(5):485-91.
91. Cressey TR, Van Dyke R, Jourdain G, et al. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. Antimicrob Agents Chemother. 2009;53(5):2189-91.
92. Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54(4):381-8.
93. Ramautarsing RA, van der Lugt J, Gorowara M, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS. 2011;25(10):1299-303.
94. van der Leur MR, Burger DM, la Porte CJ, et al. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006;28(5):650-3.
95. Bouillon-Pichault M, Jullien V, Piketty C, et al. A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients. Antivir Ther. 2009;14(7):923-9.
96. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother. 2001;45(4):1086-93.
97. Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003;17(8):1195-9.
98. Bryson YJ, Mirochnick M, Stek A, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008;9(2):115-25.
99. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62(3):309-15.
100. Read JS, Best BM, Stek AM, et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008;9(10):875-82.
101. Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2(6):460-5.
102. Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48(2):430-6.
103. Martinez-Rebollar M, Lonca M, Perez I, et al. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. Ther Drug Monit. 2011;33(6):772-7.
104. von Hentig N, Nisius G, Lennemann T, et al. Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther. 2008;13(8):1039-46.
105. van der Lugt J, Colbers A, Molto J, et al. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009;14(3):443-50.
106. King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet. 2006;45(7):665-82.
107. Weizsaecker K, Kurowski M, Hoffmeister B, et al. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS. 2011;22(5):294-5.
108. Raltegravir (Isentress) [package insert]. Whitehouse Station: Merck Sharp & Dohme Corp.; 2011.
109. Best BM, Capparelli E, Stek A. Raltegravir pharmacokinetics during pregnancy [abstract no. H-1668a]. In: Programs and abstracts of the 50th interscience conference on antimicrobial agents and chemotherapy; 2010 Sep 12-15; Boston, MA. Washington, DC: American Society for Microbiology Washington, DC; 2010.
110. Colbers A, Molto J, Ivanovic J. A comparison of the pharmacokinetics of raltegravir during pregnancy and post-partum [abstract no. P-18]. In: Programs and abstracts of the 12th international workshop on clinical pharmacology of HIV therapy; 2011 Apr 13-15; Miami, Florida. Utrecht: Virology Education B.V.; 2011.
111. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15(4):677-80.
112. Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother. 2010;65(9):2050-2.
113. Maraviroc (Selzentry) [package insert]. Freiburg: Pfizer Manufacturing Deutschland GmbH; 2010.
114. Winters MA, Van Rompay KK, Kashuba AD, et al. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother. 2010;54(10):4059-63.
115. Enfuvirtide (Fuzeon) [package insert]. South San Francisco: Genentech USA, Inc.; 2011.
116. Brennan-Benson P, Pakianathan M, Rice P, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS. 2006;20(2):297-9.
117. Nakamura Y, Ikeda S, Furukawa T, et al. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun. 1997;235(3):849-53.
118. Molsa M, Heikkinen T, Hakkola J, et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther. 2005;78(2):123-31.
119. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis. 2005;192(5):713-9.
120. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8(3):e1000430.
121. Breitzka RL, Sandritter TL, Hatzopoulos FK. Principles of drug transfer into breast milk and drug disposition in the nursing infant. J Hum Lact. 1997;13(2):155-8.
122. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53(3):1170-6.
123. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr. 2008;48(4):450-4.
124. Spencer L, Neely M, Mordwinkin N. Intensive pharmacokinetics of zidovudine, lamivudine, and atazanavir and HIV-1 viral load in breast milk and plasma in HIV + women receiving HAART. In: Programs and abstracts of the 16th conference on retroviruses and opportunistic infections; 2009 Feb 8-11; Montreal, CA. Alexandria: Foundation for Retrovirology and Human Health; 2009.
125. Weidle PJ, Zeh C, Martin A, et al. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother. 2011;55(11):5168-71.
126. Kromdijk W, Mulder JW, Rosing H, et al. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J Antimicrob Chemother. 2012;67(5):1211-6.
127. Azoulay S, Nevers MC, Creminon C, et al. An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients. J Immunol Methods. 2004;295(1-2):37-48.
128. Roucairol C, Azoulay S, Nevers MC, et al. Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells. Antimicrob Agents Chemother. 2007;51(2):405-11.
129. Cressey TR, Nangola S, Tawon Y, et al. Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2007;51(9):3361-3.
130. Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48(11):4332-6.
131. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20(13):1737-43.
132. WHO HIV/AIDS Programme. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective. Geneva: WHO; 2012 Jun. http://www.who.int/hiv/pub/treatment2/efavirenz/en/index.html. Accessed 26 Jul 2012.